Clinical Trial

Use of the ECG Watch in Palpitation Assessment: Feasibility Study

Study acronym: WATCH-RHYTHM
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
Palpitations are the cause of 16% of reasons for consultation with the general practitioner. 41% of palpitations are secondary to cardiac arrhythmia. If a rhythm or conduction disorder is recorded in a symptomatic context, then the cardiac origin can be validated or invalidated. The challenge therefore consists of obtaining an ECG trace during an attack of palpitations (per-critical ECG). Since patients are rarely symptomatic during consultations, additional exploration by ambulatory electrocardiographic recording is essential. To date, the 24-hour Holter ECG is currently the most used in current practice, only has a sensitivity of 22 to 35% maximum depending on the studies. We hypothesize that the ECG watch is a reliable medical tool in the etiological assessment of palpitations, with at least 90% of traces interpretable. The main objective of this study is to validate the use of the ScanWatch watch (Withings®) in the assessment of palpitations.
Trial Details
NCT Number NCT07121816
Lead Sponsor University Hospital, Clermont-Ferrand
Collaborators: Hôpital Haut-Lévêque, University Hospital, Toulouse
Conditions Palpitation
Enrollment 120 participants
Start Date 2025-09-01
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-09-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-14